Glaukos Raises Full-Year Revenue Forecast, Enters 30-Week Base Buy Zone
GKOS•Glaukos raised its full-year revenue forecast following its latest quarterly report on stronger-than-expected sales of its micro-invasive glaucoma surgery devices. Shares are trading within the buy zone of a 30-week base chart, indicating potential entry opportunity after the upbeat guidance.
1. Revenue Forecast Upgrade
In its latest quarterly report, Glaukos raised its full-year revenue forecast, citing robust demand for its micro-invasive glaucoma surgery (MIGS) devices that outpaced prior guidance.
2. Technical Chart Setup
The stock has entered the buy zone of a 30-week base chart pattern, a technical signal suggesting that the shares may be poised for a sustained advance following the forecast upgrade.
3. Upcoming Q2 Results
Glaukos will release its second-quarter 2026 financial results on July 29 after market close, offering investors a fresh update on sales trends and margin performance.
